278 related articles for article (PubMed ID: 23497555)
1. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F
Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555
[TBL] [Abstract][Full Text] [Related]
2. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
[TBL] [Abstract][Full Text] [Related]
4. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
5. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
6. Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
Wurstbauer K; Deutschmann H; Kopp P; Kranzinger M; Merz F; Nairz O; Studnicka M; Sedlmayer F
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1345-51. PubMed ID: 19910140
[TBL] [Abstract][Full Text] [Related]
7. DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (I/II) non-small-cell lung cancer.
Zehentmayr F; Wurstbauer K; Deutschmann H; Fussl C; Kopp P; Dagn K; Fastner G; Porsch P; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2015 Mar; 191(3):256-63. PubMed ID: 25245469
[TBL] [Abstract][Full Text] [Related]
8. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
Ajlouni M; Chapman R; Kim JH
Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
[TBL] [Abstract][Full Text] [Related]
9. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
[TBL] [Abstract][Full Text] [Related]
10. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Campeau MP; Herschtal A; Wheeler G; Mac Manus M; Wirth A; Michael M; Hogg A; Drummond E; Ball D
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1371-5. PubMed ID: 19250769
[TBL] [Abstract][Full Text] [Related]
11. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
12. The impact of induction chemotherapy on the dosimetric parameters of subsequent radiotherapy: an investigation of 30 consecutive patients with locally-advanced non-small cell lung cancer and modern radiation planning techniques.
Grant JD; Sobremonte A; Hillebrandt E; Allen PK; Gomez DR
Radiat Oncol; 2015 Jan; 10():32. PubMed ID: 25636372
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
[TBL] [Abstract][Full Text] [Related]
14. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
Ouyang WW; Su SF; Ma Z; Hu YX; Lu B; Li QS; Geng YC; Li HQ
Radiat Oncol; 2014 Jun; 9():147. PubMed ID: 24962716
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
[TBL] [Abstract][Full Text] [Related]
17. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
[TBL] [Abstract][Full Text] [Related]
18. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
[TBL] [Abstract][Full Text] [Related]
19. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer.
Willner J; Baier K; Caragiani E; Tschammler A; Flentje M
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):382-9. PubMed ID: 11872283
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
